Efficacy of oral nalbuphine extended release for the treatment of chronic cough in idiopathic pulmonary fibrosis: Analysis of a Phase 2 study

This randomized, double-blind, crossover trial examined the effects of an extended-release formulation of nalbuphine in 32 adult patients with IPF-related chronic cough. The primary endpoint was the percent change from baseline in hourly daytime cough frequency, which was objectively measured using the Vitalograph VitaloJAK digital cough monitor.